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Joint sequencing of human and pathogen genomes
reveals the genetics of pneumococcal meningitis
John A. Lees et al.#
Streptococcus pneumoniae is a common nasopharyngeal colonizer, but can also cause life-
threatening invasive diseases such as empyema, bacteremia and meningitis. Genetic variation
of host and pathogen is known to play a role in invasive pneumococcal disease, though to
what extent is unknown. In a genome-wide association study of human and pathogen we
show that human variation explains almost half of variation in susceptibility to pneumococcal
meningitis and one-third of variation in severity, identifying variants in CCDC33 associated
with susceptibility. Pneumococcal genetic variation explains a large amount of invasive
potential (70%), but has no effect on severity. Serotype alone is insufﬁcient to explain
invasiveness, suggesting other pneumococcal factors are involved in progression to invasive
disease. We identify pneumococcal genes involved in invasiveness including pspC and zmpD,
and perform a human-bacteria interaction analysis. These genes are potential candidates
for the development of more broadly-acting pneumococcal vaccines.
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S treptococcus pneumoniae, or the pneumococcus, is theleading cause of bacterial meningitis, which is an importantcause of mortality and morbidity worldwide despite
advances in vaccination and treatment1,2. The case fatality rate of
pneumococcal meningitis is 17–20% and unfavourable outcome
occurs in 38–50% of cases3. S. pneumoniae is also the leading
cause of pneumonia and bacteremia. Invasive disease is preceded
by nasopharyngeal colonization3.
Knowledge of the contribution of genetic variability of humans
and invading pathogens to pneumococcal meningitis suscept-
ibility could guide development of new vaccines preventing the
progression from asymptomatic carriage to invasive disease,
whereas genetic variation associated with disease severity may
guide new clinical intervention strategies during treatment4.
However, the overall effect of human genetics on pneumococcal
meningitis is unknown—whether it affects the disease at all, and if
so, which speciﬁc regions of the genome cause the effect. His-
torically, genetic association studies on bacterial meningitis have
been held back by only assessing candidate genes, small sample
sizes or poorly deﬁned phenotypes5. More recent host genome-
wide association studies (hGWASs; glossary Table 1) have found
associations of a protective variant in complement factor H
(CFH) for children with meningococcal meningitis in Europe6,
between a long non-coding RNA and pneumococcal meningitis
in children in Kenya7 and between CA10 and self-reported bac-
terial meningitis8.
In terms of pathogen variability, it is well known that the
pneumococcal polysaccharide capsule, which determines its ser-
otype, contributes to invasive propensity9,10. The pneumococcal
genome also encodes a variety of proteins that directly interact
with the host, mostly to enhance colonization and avoid the host
immune response11. Mouse models have shown that some anti-
gens such as pspC (cbpA) enhance virulence but are not essential
in invasive isolates12,13. While it is known that these antigens
have a role in colonization and disease, whether sequence varia-
tion at these loci has an effect on pathogenesis in human disease
remains unclear. Previous small association studies have addi-
tionally suggested a role for platelet binding14 and arginine
synthesis15 in pneumococcal meningitis, and analysis of within-
host variation found that sequence variation of dlt and pde1 are
associated with pneumococcal meningitis16,17.
Pathogen GWASs (pGWASs) provide a way to identify
pneumococcal sequence variation associated with meningitis,
independent of genetic background and in an unbiased manner.
While GWAS is more challenging in bacteria than in humans due
to strong population structure and high levels of pan-genomic
variation, recent methodological advances have helped overcome
these issues18–20.
Here, we use data and samples from Dutch adults in our
prospective and nationwide MeninGene cohort3. We have col-
lected a large number of samples of both human and pathogen
DNA from culture-proven cases of pneumococcal meningitis,
along with detailed clinical metadata (Supplementary Tables 1
and 2). Genotyping and whole-genome sequencing of this col-
lection allows us to undertake a combined GWASs of host
(hGWASs) and pathogen (pGWASs) in pneumococcal menin-
gitis. We further include an analysis of interaction effects in a
joint GWAS and replicate our ﬁndings in additional cohorts of
invasive pneumococcal disease (IPD; Fig. 1). Our analyses deﬁne
the role of genetic variation of host and pathogen in pneumo-
coccal meningitis.
Results
Multiple bacterial loci determine pneumococcal invasiveness.
We ﬁrst calculated the heritability of susceptibility and severity
due to pneumococcal genetics using the MeninGene cohort. The
heritability corresponds to the proportion of phenotypic variation
explained by genetics, in this case single-nucleotide polymorph-
ism (SNP) variation in the bacterial core genome. We used an
additive binary phenotype model, which does not model any
potential effects of genetic interactions (either epistatic or with
the environment)21. Under this model, we found that additive
pneumococcal genetics explained much of variation in invasive
propensity (h2SNP= 70%) but not meningitis disease severity
(h2SNP= 0%). We also calculated that 31% of the phenotypic
variance could be explained by the top ten principal components,
which explained 67% of the total genetic variance. This suggests
that lineage effects, as in those pneumococcal strains which are
more likely to be sampled from an invaded niche, only partially
account for the estimated heritability. It may therefore be possible
to ﬁnd additional speciﬁc locus effects.
These h2SNP estimates suggest that invasive propensity is highly
dependent on pneumococcal genome content but that disease
outcome is not determined by natural variation of pathogen
genetics. The latter is not surprising as invasive disease is an
evolutionary dead end for the pathogen, so adaptations affecting
virulence over the short course of infection are unlikely to be
selected for. This is contrary to smaller studies suggesting that
bacterial genotype may predict disease severity22 but consistent
with a meta-analysis ﬁnding no effect of pneumococcal serotype
on the risk ratio of death from meningitis23. In our population,
levels of antimicrobial resistance are low and rarely led to
treatment failure. In populations where resistance leads to
treatment failure, ﬁnding h2 > 0 for severity could be expected.
The high heritability estimated here is consistent with the fact
that some serotypes are rarely found in invasive disease9, and
invasive lineages are genetically divergent from the rest of the
population. It should also be noted that all meningitis isolates
were once carriage isolates, which by our sampling scheme are
effectively overrepresented in an invaded niche. Some of the
poorly invasive yet highly transmissible strains usually observed
in carriage may also be able to cause invasive disease, potentially
meaning heritability is slightly underestimated.
Pneumococcal serotype is the current focus of vaccination.
Using the same framework as for core SNPs, we calculated the
proportion of variation in invasiveness that can be attributed to
Table 1 Glossary of terms
Term Meaning
CSF Cerebrospinal ﬂuid
IPD Invasive pneumococcal disease
GWAS Genome-wide association study
hGWAS Host genome-wide association study
pGWAS Pathogen genome-wide association study
h2 Heritability (variation in phenotype explained by genetic
variation)
OR Odds ratio
LD Linkage disequilibrium
MAF Minor allele frequency (of the least common allele observed in
the population)
AF Allele frequency (presence of gene or versus reference allele)
LoF Loss of function (frameshift or nonsense mutation in protein)
SFS Site frequency spectrum (histogram of minor allele
frequencies)
LMM Linear mixed model (association model used in genome-wide
association study)
eQTL Expression quantitative trait loci (genetic association with
transcript variation)
LD Linkage disequilibrium
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serotype collectively, ﬁnding h2serotype= 50% (77% of h2SNP). A
model including both serotype and other genetic factors was
supported over non-serotype relations alone (likelihood ratio test
p < 10–10), but decomposing these variance contributions quanti-
tatively was not possible due to their correlation. Overall, this
provides some evidence that serotype affects invasive potential
independently of genetic background, but the strength of this
conclusion is ultimately limited due to the covariance of these two
factors. However, in considering whether serotype is the
dominant factor in invasiveness, h2serotype < h2SNP means we can
more conﬁdently expect that other pneumococcal loci are also
involved in invasion.
A potential role of rare variation in pneumococcal invasion.
We evaluated differences in the sequence variation between
asymptomatic carriage and meningitis isolates. The amount of
rare variation compared to common variation is informative of
recent selection and population size changes24. An overall dif-
ference may be informative of different selection on regions of the
genome depending on the niche. In Fig. 2a, we have plotted the
site-frequency spectrum by niche and predicted consequence.
Across the range of common minor allele frequencies (MAFs) in
both niches, the proportion of synonymous/nonsynonymous/
intergenic/loss-of-function (LoF) mutations is as previously
observed25; at low frequencies, there is an excess of potentially
damaging variants. Figure 2c shows the overall burden of
damaging rare variants between carriage and invasive samples; in
both LoF and damaging variants, there was higher burden in
carriage isolates (median LoF: invasive 7, carriage 11, two-tailed
Wilcoxon rank-sum test W= 303,070, p < 1 × 10–10; median
damaging: invasive 22, carriage 26, Wilcoxon rank-sum test W=
350,690, p= 3 × 10–5). When correcting for the number of
synonymous mutations, treated as neutral, in each sample there
was still a higher excess burden of rare LoF and damaging var-
iants in carriage isolates (damaging: two-tailed Wilcoxon rank
sum test W= 301,820, p < 1 × 10–10; LoF: two-tailed Wilcoxon
rank-sum test W= 357,220, p= 0.001). In the absence of popu-
lation size change, this implies that certain genes are under
stronger purifying selection in invasive lineages, with damaging
mutations which still allow carriage being purged in the invasive
population. We therefore attempted to quantify the amount of
phenotypic variation due to the burden of rare damaging and LoF
mutations but were unable to directly ﬁnd signiﬁcant evidence for
susceptibility h2burden > 0 for any individual gene or over all genes.
However, this calculation is underpowered due to the small
number of rare mutations.
Instead, to quantify the difference in rare variants between
invasive and carriage samples and to identify which regions of the
genome are responsible for the excess of rare alleles we calculated
Tajima’s D, a statistic for determining departures from neutral
evolution, for each coding sequence in the genome, and looked
for differing signs of selection between cases and controls.
Deviations with D < 0 are indicative of selective sweeps and/or
recent population expansion, whereas D > 0 is indicative of
balancing selection and/or recent population contraction. We
compared the distributions of D by gene in each phenotype
(Fig. 2b). Genes in invasive isolates had a lower average D
(difference in medians −0.34; two-tailed Wilcoxon rank-sum test
W= 1996100, p < 10–10) and a more positively skewed D
(difference in skewness 0.30; 95% bootstrapped conﬁdence
interval 0.17–0.44). This difference in D may be representative
of a genuine difference in selection of variants in genes between
niche or may be due to a difference in recent population
dynamics, for example, due to the bottlenecks for invasion and
transmission. It is illustrative to evaluate these ﬁndings consider-
ing invasive population as a sample from the carriage population,
with potentially invasive genotypes ampliﬁed. A greater average D
is not observed, as would be caused by rare variants becoming
common through random subsampling through a bottleneck. The
ﬁnding of a lower average D would not necessarily always be
expected from subsampling low diversity invasive clones from the
overall population. Instead, the shift towards lower MAFs
suggests that some allelic variants or genotypes found in carriage
are disadvantageous in invasive disease or that recent, rare
mutations may play a role in invasion.
Identiﬁcation of speciﬁc pneumococcal invasiveness loci. We
then tried to ﬁnd pneumococcal factors other than serotype that
are associated with disease. We ﬁrst performed a pGWAS with
disease severity in the Dutch MeninGene cohort. Consistent with
our estimates of no heritability, we found no loci of any type to be
signiﬁcantly associated with severity.
We then analysed meningitis versus carriage isolates. We ﬁrst
analysed each of our cohorts individually (Supplementary
Tables 4–6), and in an effort to make our results applicable
across more of the species, we also combined the Dutch cohort of
meningitis and carriage samples with a cohort collected in South
Africa. This cohort included samples from carriage and cases of
IPD. These isolates were from a heterogeneous population,
around 15% of which were meningitis cases. While not an
identical phenotype to the meningitis cases collected in the Dutch
cohort, these phenotypes do overlap (all meningitis cases are IPD
cases by deﬁnition). It was also recently shown, for a single
population, that pneumococcal genomes from non-meningitis
IPD are highly similar to meningitis IPD26. However, as there are
many different infection routes, this approach will only be
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Fig. 1 Overview of cohorts sequenced and associations performed. Left, host data; right, bacterial data; the centre represents samples with both host and
pathogen sequence data. Samples in green are those collected from our MeninGene cohort that form the centre of this work. Owing to unbalanced
case–control ratios, we show the effective sample size, speciﬁc numbers of cases and controls of human genotypes in Supplementary table 2
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powered to detect those routes common between the cohorts—
most likely invasion into the bloodstream.
This pooling of cohorts gave a total of 5845 pneumococcal
genomes to analyse (Fig. 3). Carriage and invasive isolates (cases
and controls) are distributed across the tree, though with clear
clusters also associated with a single serotype. The two cohorts
were genetically separated, with lineages generally at very
different frequencies in each population. We controlled for this
in two ways. First, by performing a pooled pGWAS both with the
sample cohort as a covariate in our analysis and a co-estimated
kinship matrix as random effects (Table 2). We also combined
separate association studies in our two cohorts using a meta-
analysis (Table 3), which more easily allows difference in
direction and size of effect in each cohort to be seen.
Table 2 shows the genes that were signiﬁcant in this combined
analysis using any of our association methods – due to cohort
heterogeneity they should be considered as hypotheses for
association with natural IPD. The genes noted in bold font in
Table 2 are all immunogenic27 and have been associated with
pneumococcal virulence in animal models12,28–30 but not yet in
patients with invasive disease. A k-mer in pspC, signiﬁcant in the
pooled analysis, was signiﬁcant in the South African cohort but
not in the Dutch cohort. However, we found that the presence of
other non-overlapping k-mers in pspC in each cohort was
associated with invasive disease with the same direction of effect
(maximum p-value pSA= 9.7 × 10–13; pNL= 1.3 × 10–9). We
predicted that both forms of pspC were absent in 13 meningitis
isolates, though manual inspection of the summary statistics from
mapping and assembly suggested these may also be an unresolved
form of allele 8. Previous conclusions, drawn from protein
binding to the laminin and polymeric immunoglobulin receptors,
have suggested that pspC (cbpA) is necessary for meningitis31. All
13 patients infected by these strains had a severe ear, nose or
throat infection, suggestive for direct spread of bacteria rather
than crossing the blood–brain barrier. Three patients had clear
bone destruction and/or pneumocephalus and one patient had a
skull defect due to previous surgery. We further tested whether
the two major forms of PspC were associated with meningitis, as
has previously been suggested32, but did not ﬁnd either to be
overrepresented, when accounting for population structure. dacB
is involved in preserving cell wall shape and has shown to
attenuate virulence in a mouse model of lung infection28. This
gene is highly expressed in early stages of infection, until
expression declines after 2 hrs33,34. zmpD is homologous to IgA1
protease (zmpA)35, and while it is immunogenic27, its function is
unknown. A previous study in asymptomatic carriage found it to
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Fig. 2 Burden of rare variation between invasive and carriage isolates, based on mapping and calling short variants against a single reference genome. Loss-
of-function (LoF) are frameshift or nonsense mutations. a The site frequency spectrum (SFS) stratiﬁed by niche and by predicted consequence. Frequency
has been normalized with respect to the number of samples in each population. b Histogram of Tajima’s D for all coding sequences in the genome,
stratiﬁed by niche. c Boxplot of the number of rare variants per sample, stratiﬁed by niche and predicted consequence. Damaging mutations are LoF
mutations and missense mutations predicted damaging by PROVEAN. Centre line is the median, box spans lower to upper quartiles. Whiskers show the
outlier range, deﬁned as being >1.5× the interquartile range above or below the lower and upper quartiles
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be more prevalent in older children36. The results from our
pGWAS suggest a role in human cases of disease. This result
seems to primarily be driven by singleton variants observed in
invasive samples, which occur repeatedly at the tips of the tree
(Supplementary Fig. 1).
The other genes in Table 2 have not previously been directly
associated with virulence or invasive disease in S. pneumoniae.
SPN23F09820 (FM211187.3090) is a protein of unknown
function, which is annotated as bacteriocin precursor. There
was no difference in its expression between simulated blood,
cerebrospinal ﬂuid (CSF) and infection conditions33. While
different alleles of bacteriocins are known to be involved in
cell–cell bacterial competition, whether a relation between allelic
variation and pathogenesis exists is unknown. SPN23F05670
(FM211187.1804) is usually directly upstream of dacB, which it is
coexpressed with, and therefore likely represents the same signal.
Other pneumococcal proteins containing the histidine triad
(HIT) motif are expressed on the cell surface and bind human
complement37, but little is known about the speciﬁc function of
this protein or its relationship with disease. When compared to
the nasopharynx, ecsA is downregulated in CSF, blood and
infection conditions. While in other species this gene has been
associated with cell–cell interactions38 and virulence39, in
S. pneumoniae allelic variants of ecsA have been previously
correlated with serotype in carriage40, so this may be linked with
the effect of capsule. Finally, mutations in mcrB, an endonuclease
that is more highly expressed in infection conditions, have been
shown to lead to phage resistance41. Phages may have a number
of different effects on the bacterial host cell, including loss of
competence, changes in ﬁtness or bringing in virulence cargo
genes, but as we did not detect any of these elements directly
through our pGWAS we cannot speculate further.
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Fig. 3 Phylogenetic tree of all samples included in the pathogen genome-wide association study. Rings show metadata about samples, from inside to
outside: phenotype (carriage or invasive); cohort (Netherlands or South Africa); common serotypes; patient age on a continuous scale from younger
(white) to older (blue). Scale bar: 0.01 substitutions per site. An interactive version is available at https://microreact.org/project/Spn_GWAS/9eb0bd5d
(project link https://microreact.org/project/Spn_GWAS)
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We also observed hits (not shown in Tables 2 and 3) to
simple transposons without cargo genes, which we therefore
discarded as we assumed this was an artefact of their
independence from population structure. We also found
signiﬁcant association of some BOX repeats42, but as there are
many copies we could not map these associations to a single
region of the genome.
It is notable that many of our pGWAS results were due to
rare genetic variation. This variation may be more important in
a disease like meningitis where there is no pervasive selection for
the phenotype and effects are likely polygenic, as opposed to the
strong monogenic effects seen for many antimicrobial resistance
traits. Mutations with the same functional effect that occur at the
tips of the tree are less confounded by population structure and
therefore a signal that is easier to ﬁnd with pGWAS. In the
missense burden test, we are able to combine lineage variants
that are heavily population stratiﬁed and therefore contribute
only a small amount of information in relation to the number of
samples they are found in, with functionally similar mutations
elsewhere in the tree. Overall the invasive disease-associated genes
had no propensity to accumulate missense variants (median dN/dS
core genes= 0.25; median dN/dS hit genes= 0.28; Wilcoxon rank-
sum test W= 2741, two-tailed p value= 0.9414), suggesting the
power increase is more likely due to population structure rather
than mutation frequency. If these repeated functional changes
were the only biological explanation for invasiveness, this would
suggest that there exists a group of protein alleles that are more
able to cause invasive disease, consistent with the Tajima’s D
results above.
Human genetics associates with susceptibility and severity. In
contrast to bacteria, human variation within populations of the
same ancestry is not strongly confounded by population struc-
ture, and only sites in relatively close physical proximity show
any correlation43. Mapping associations within the resolution
of a single locus is therefore generally easier than in pGWAS,
with LMMs again able to control for genetic background
(in this case caused by differences in ancestry within the sampled
population)44. Precise control of ancestry also allows for the
comparison with genetic, transcriptomic and physical distance
based associations from other cohorts, even when the ancestry
of the cohorts are not exactly matched45. For these purposes,
summary statistics (effect size, direction and p-value) of asso-
ciations is often sufﬁcient to combine data from different studies
and data sources.
Table 2 Signals of bacterial association in a pooled analysis
Gene ID Gene name Gene population
frequency
Method OR/effect size p-value Function
SPN23F05680 ldcB/dacB 0.81 Missense burden
in invasive
1.20 1.3 × 10–19 D-alanyl-D-alanine carboxypeptidase
(peptoglycan peptide precursors)
SPN23F22240 pspC/cbpA 0.59 K-mers 1.05 3.8 × 10–13 Binds secretory IgA, C3 and
complement factor H; adhesin
SPN23F08080 spnTVR hsdS 1.00 Missense burden
in invasive
1.08 2.8 × 10–6 Type I restriction-modiﬁcation
system speciﬁcity subunit S
SPN23F17820 psrP 0.42 Tajima’s D −2.71 (invasive)
−2.59 (carriage)
<1 × 10–6 adhesin
SPN23F10590 zmpD 0.53 Burden of rare LoF
in invasive
1.42 <1 × 10–10 Unknown; paralogous to IgA1
protease (zmpA)
SPN23F09820 FM211187.3090 0.36 Missense burden
in invasive
1.30 3.4 × 10–49 Bacteriocin precursor
SPN23F05670 FM211187.1804 1.00 Missense burden
in invasive
1.27 4.3 × 10–47 Histidine triad family protein
(nucleotide phosphatase)
SPN23F04740 ecsA 1.00 Missense burden
in invasive
1.15 1.4 × 10–8 ABC transporter ATPase
SPN23F11460 mcrB — Missense burden
in invasive
1.13 1.2 × 10–6 Endonuclease
Combining The Netherlands (meningitis only) and South African (all IPD cases) cohorts into a single dataset and performing a pGWAS with cohort as a covariate. Table shows genes signiﬁcant (after
applying a Bonferroni correction for the number of tests and association methods p < 0.05) in a pooled analysis of both cohorts with any of the association approaches, ordered by p-value. Odds ratios
are with respect to carriage samples. The four genes in bold at top of the table are immunogenic and have previous evidence for association with virulence. For Tajima’s D, the effect size is the difference
between D values, and for k-mers and LoF burden tests it is the odds ratio. For some p values, the calculation only allows an upper bound to be produced. The locus tag in the ATCC 700669 reference is
listed, along with the common gene name if available
OR odds ratio
Table 3 Meta-analysis of signals of bacterial association
Gene ID Gene name OR (NL) p-value (NL) OR (SA) p-value (SA) Combined p-value
SPN23F05680 ldcB/dacB 1.39 2.8 × 10–19 1.13 9.6 × 10–8 5.4 × 10–21
SPN23F22240 pspC/cbpA 1.00 8.1 × 10–1 1.12 4.7 × 10–12 5.3 × 10–11
SPN23F08080 spnTVR hsdS 0.82 1.9 × 10–4 1.09 4.2 × 10–6 7.5 × 10–2
SPN23F17820 psrP −2.27 (invasive)
−0.14 (carriage)
<1 × 10–6 −2.61 (invasive)
−2.62 (carriage)
4.5 × 10–4 <1 × 10–6
SPN23F10590 zmpD 1.17 8.6 × 10–13 1.12 2.5 × 10–5 8.4 × 10–14
SPN23F09820 FM211187.3090 1.37 5.0 × 10–23 1.30 1.9 × 10–33 3.4 × 10–54
SPN23F05670 FM211187.1804 1.47 1.8 × 10–30 1.22 2.9 × 10–25 8.3 × 10–51
SPN23F04740 ecsA 1.20 1.8 × 10–7 1.11 9.7 × 10–4 1.8 × 10–8
SPN23F11460 mcrB 1.45 3.7 × 10–8 1.11 9.5 × 10–5 1.2 × 10–6
As in Table 2, showing behaviour of signals in The Netherlands (NL) and South African (SA) cohorts individually. The p value is from meta-analysis of the two cohorts using METAL to compute a
combined z value, so is different from the p value in Table 2, which was computed by applying an LMM to all samples
OR odds ratio
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Being the most studied genome of any species, a wealth of
information on human genes is available to further interpret
genetic variants with relatively unknown function. Using data
from the GTEx consortium (an expression quantitative trait locus
(eQTL) study across 44 different tissues, wherein genetic variants
are tested for association with changes in the expression levels
across the transcriptome)46,47, effects on expression on more
distant genes or in speciﬁc tissues can be noted. Additionally, as
eukaryotic DNA is tightly packed within the nucleus, longer-
range interactions may exist between sites that are close in three-
dimensional space but apparently distant along a one-
dimensional genomic coordinate axis. These long-range interac-
tions may, for example, function as enhancers, boosting the
expression of distant genes in certain cell types. Chromatin
conformation capture (Hi-C) data can ﬁnd interaction partners
across the genome in a range of cell types48, which then may offer
additional insight into effects of a variant beyond its immediate
genomic region, and in which cells this interaction is important.
Using the human genotyping data we produced, we were also
able to apply LMMs to calculate heritability due to host genetics
and identify common SNP variation in humans that predisposes
to the measured phenotypes. To acquire sufﬁcient cases to
accurately estimate heritability, we combined severe pneumococ-
cal cases (Ncases= 212) with severe cases from any pathogen
(Ncases= 277). To justify this, we reasoned that the enormous
difference in host inﬂammatory response observed between these
phenotypes may well be through the same host mechanism,
irrespective of the speciﬁc infecting bacteria3. We then used two
standard methods to calculate SNP heritability, which both
showed that variation in host genetics explains 29% ± 7% of the
observed variation in pneumococcal meningitis susceptibility and
49% ± 14% of the variation in meningitis severity (Table 4). These
are relatively large genetic contributions compared to other
infectious diseases8.
Next, we performed a hGWAS to search for speciﬁc loci
associated with meningitis. We did not ﬁnd any associations
reaching signiﬁcance for severe pneumococcal meningitis, but
when combined with severe meningitis from all other species (as
in the heritability calculations) one marker reached signiﬁcance
when testing for severity: position 64680775 (rs12081070) on
chromosome 1, an intronic variant in UBE2U that was associated
with unfavourable outcome (MAF= 0.43; odds ratio (OR)= 1.63;
p= 2.0 × 10–8) (Supplementary Figs. 2–5). UBE2U is part of the
ubiquitin pathway and is involved in antigen presentation
through the class I major histocompatibility complex pathway49
but has not been previously directly associated with any disease or
trait in a genetic study.
We used existing data from chromatin conformation capture
to ﬁnd possible interaction partners of these loci in various cell
types. This analysis showed that the site of the most signiﬁcantly
associated variant (rs12081070) interacts with PGM1 and ROR1
in a range of immune cell types, including monocyte/macro-
phages, CD4/8 T cells, B cells and neutrophils (Supplementary
Fig. 5). PGM1 encodes a phosphoglucomutase while ROR1 is a
protein of unknown function that has previously been associated
with cancers50 and pulmonary function51. Using the GTEx
database of gene expression across different human tissues, we
found evidence of association of rs12081070 with gene expression
in a panel of tissues and cell types, but this was only signiﬁcant in
one (skin—p= 5.7 × 10–13)47. Six other loci showed suggestive
signiﬁcance (Table 5), whereas in the Danish cohort, no variants
reached genome-wide signiﬁcance (Supplementary Figs. 7 and 8).
Of the genes putatively implicated in meningitis in the
MeninGene cohort at the suggestive level, we noted that the
ME2 promoter variant rs2850542 is an eQTL for the same gene in
whole blood (p= 5.9 × 10–20, Supplementary Fig. 9A) and
speciﬁcally in monocytes (false discovery rate 5.1 × 10–26)52.
There was also evidence of chromatin interaction of the variant
location with SMAD4 again in a range of immune cell types
including monocytes, lymphocytes and neutrophils (Supplemen-
tary Fig. 9B, C). SMAD4 is a key intracellular mediator of
transcriptional responses to transforming growth factor beta and
involved in the invasion across the epithelium; the variant also
showed evidence of an eQTL involving rs2850542 for SMAD4
expression in tibial artery (p= 8.6 × 10–7)53. These data tenta-
tively suggest that the expression of these genes in the noted
tissues, speciﬁcally blood, may be the means by which suscept-
ibility to meningitis is affected.
As with the pGWAS, to improve our discovery power and
mitigate false positives from cohort-speciﬁc batch effects, we
performed similar associations in the other cohorts. The results
for susceptibility to meningitis (MeninGene, Danish meningitis,
UK biobank ICD-10 code for meningitis) found that position
74601544 on chromosome 15 (rs116264669) was associated
with the minor allele increasing susceptibility in all three studies
(p= 4.4 × 10–8; MAF= 3%) (Supplementary Figs. 10 and 11).
This intronic SNP is located in CCDC33, a gene that has no prior
Table 4 Human SNP heritability (h2SNP) of meningitis in the
MeninGene cohort
Phenotype Method Heritability Error p-value
Susceptibility
(pneumococcal)
GCTA 0.25 0.05 2.4 × 10–6
LDAK 0.29 0.07 3.9 × 10–6
Severity (any
species)
GCTA 0.29 0.11 2.8 × 10–5
LDAK 0.49 0.14 1.4 × 10–4
Heritability for susceptibility and severity of meningitis in Dutch adults. Heritabilities are shown
on the liability scale (adjusted for population prevalence and case ascertainment ratio). We used
two methods for each phenotype, GCTA and LDAK. The latter corrects for linkage
disequilibrium when estimating the kinship between genotypes. All results showed
signiﬁcant (p < 0.05) evidence for a heritability above zero
Table 5 Signals of human association in the MeninGene cohort
Phenotype Position (SNP) Marker Effect allele MAF OR p-value
Annotation
Susceptibility (pneumococcal meningitis only) chr6:117624549 (rs210967) G 0.46 0.77 8.8 × 10–7 ROS1 intronic
chr18:48403560 (rs2850542) T 0.43 0.65 7.6 × 10–8 ME2 promoter
(2 kb upstream of TSS)
chr22:47506160 (rs13057743) G 0.33 0.74 5.5 × 10–7 TBC1D22A intronic
Severity (any species) chr1:64680775 (rs12081070) A 0.43 1.62 2.0 × 10–8 UBE2U (ﬁfth intron)/ROR1
chr4:182823804 (rs2309554) A 0.33 1.58 4.1 × 10–7 AC108142.1 intron
chr9:37382231 (rs72739603)
A 0.07 2.36 6.7 × 10–7 ZCCHC7/GRHPR
We report the lead SNP at each putatively associated locus with MAF > 5% and p < 1 × 10–6, and nearby annotated genes. p < 5 × 10–8 is the genome-wide signiﬁcance threshold—only rs12081070
exceeds this. The suggestive signal in all meningitis cases at rs3870369 was also present when restricted to pneumococcal cases, albeit with a lower p value of 3.9 × 10–7
MAF minor allele frequency, OR odds ratio, SNP single-nucleotide polymorphism, TSS transcription start site
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association with infectious disease. CCDC33 is expressed
predominantly in the testes as well as the brain47, although there
is no evidence of an eQTL involving this variant or SNPs in
linkage disequilibrium (LD) with it. The disease-associated
variant is located in a genomic region that interacts with the
immunoglobulin superfamily containing leucine-rich repeat 2
gene ISLR2 on chromatin conformation capture analysis in
macrophages (Supplementary Fig. 12A) and CD8 T cells
(Supplementary Fig. 12B); moreover, a variant in complete LD
(rs80140040) with the meningitis susceptibility SNP shows
evidence of an eQTL with ISLR2 in a number of tissues,
including brain (p= 0.02). ISLR2 shows the highest expression in
the brain (neural tissues, Supplementary Fig. 12C) and plays a
role in the development of the nervous system54 but is poorly
characterized in humans.
Interactions between host and pathogen genomes. It is possible
that different host genotypes have varying susceptibility to dif-
ferent lineages or strains carrying certain alleles. This method of
host–pathogen analysis has previously been applied to coding
changes and host genotypes for human immunodeﬁciency virus
(HIV)55 and hepatitis C virus56, but owing to their short gen-
omes, these pathogens have many fewer variable sites than the
pneumococcal population. To test for interactions, we used the
460 samples where we had collected both human genotype and
pneumococcal genome sequence (Fig. 1). In the ﬁrst instance, to
retain hypothesis-free approach of GWAS, we performed a
host–pathogen interaction analysis between every pair of com-
mon bacterial variants and genotyped host variants. While we
were able to perform the 2 × 1010 associations required, no pairs
of loci surpassed the large multiple testing burden required by
this analysis. A power calculation showed that we would have
80% power for ﬁnding an effect with MAF of 25% and OR of 4
(Supplementary Fig. 13) in the absence of population structure,
which would only include strong and prevalent interaction
effects.
This power analysis highlights the difﬁculty of reaching
signiﬁcance for this large number of tests with a relatively small
number of samples. We then applied two further approaches in
an attempt to ﬁnd candidate interactions, with the caveat that due
to the small sample number any results would require further
validation to be conclusive. First, we considered regions with
strong prior evidence for being involved in host–pathogen
interaction. S. pneumoniae has many virulence factors, some of
which are known to interact with speciﬁc human proteins11. We
were interested in the interactions where the pneumococcal
protein contains sequence variation, not totally confounded with
genetic background. These regions have a higher power to be
detected in an association analysis, and the higher rate of
variation is potentially a sign of diversifying selection from
interactions with the human immune system. We tested for an
association between host genotype and the allele of three antigens
selected for their variability and immunogenicity: PspC (CbpA),
PspA, and ZmpA. For all of the antigen alleles with enough
observations (Supplementary Table 7), we performed an associa-
tion test against all imputed human variants as above, using a
more accurate imputation of the CFH region due to its potential
relevance in these interactions.
None of the bacterial antigen alleles were signiﬁcantly
correlated with variants in their human interacting-protein
counterparts at a genome-wide signiﬁcant or suggestive level
(p < 10–5). However, there were two associations of a pspC allele
reaching genome-wide signiﬁcance elsewhere in the genome.
Supplementary Fig. 14 shows a LocusZoom plot of each of these
associations. The ﬁrst is between pspC−8 and position 148788006
on chromosome 6 (MAF= 0.08; OR= 9.20; p= 4.1 × 10–9). This
is in SASH1, which has previously been found to have decreased
expression during meningococcal meningitis (BioProject
PRJNA106047). The second is between pspC−9 and position
98891272 on chromosome 13 (MAF= 0.16; OR= 6.30; p= 3.6 ×
10–8) in FARP1, a gene not previously associated with infectious
disease but expressed in the brain. We could ﬁnd no published
evidence of chromatin conformation capture interaction or eQTL
effects with either of these human variants.
We then attempted to reduce the multiple testing burden by
reducing the dimension of the pathogen genotype, which takes
advantage of the extensive genome-wide correlation between
variants. We used a genetic deﬁnition of pneumococcal lineages
and tested whether pathogen genotypes, so deﬁned, were
associated with host genotype. We ran associations with lineages
with at least 10% of samples in the subphenotype (Supplementary
Table 8). The only result reaching genome-wide signiﬁcance was
an association between cluster eight (serotypes 9N/15B/19A,
which have no overall association with invasive disease over
carriage) and variants on chromosome 10 (Supplementary
Fig. 15). The lead variant (rs10870273) is at position 134046136
on chromosome 10 (MAF= 0.27; OR= 4.28; p= 1.2 × 10–8)
located in an intron of STK32C, a serine/threonine kinase highly
expressed in the brain, which has also been shown to affect viral
replication57,58. The high effect sizes estimated for the interac-
tions are consistent with our power calculation (Supplementary
Fig. 13).
Discussion
Research on the role of pneumococcal variation in invasive
potential in large epidemiological studies has mostly been focused
on serotype variation. The lack of cohorts with whole genomes
and invasive phenotypes has not permitted determination of
other virulence factors in human disease—it is only with large
cohorts of whole-genome sequences that contributions to pneu-
mococcal phenotypes can be systematically attributed to serotype
or other genetic variation. With our large collection of genomes,
we were able to determine that the bacterial genome is crucial in
determining invasive potential, and while serotype is likely to be
an important factor, it alone was unable to account for the entire
genetic contribution we estimated (maximum 77% of heritability
explained). We went on to perform a combined analysis using
5892 pneumococcal genomes from two independent cohorts to
ﬁnd speciﬁc variation associated with invasive disease. We found
genes independent of genetic background and serotype to be
associated with invasive disease. This demonstrated a possible
role for the virulence genes pspC (cbpA), dacB, and psrP in human
disease and an association with the loss of the immunogenic
protein ZmpD, as well as other proteins not known to be
immunogenic. As it is impractical to cover all serotypes with the
vaccine, conserved protein targets are needed to improve cover-
age and prevent serotype replacement3. The genes discovered
here have potential as candidates that would block invasive dis-
ease in a serotype-independent manner, though further validation
of their role in invasive disease would ﬁrst be required.
Host genetics explained 29% ± 7% of variation in susceptibility
to meningitis. As blood-borne pathogen invasion is assumed to be
the route of infection in meningitis, we pooled samples from
meningitis and bacteremia cases to undertake a better-powered
hGWAS of IPD. We found a possible association at CCDC33.
This gene does not have a known function that is related to
immunity but functional genomic data suggest a possible
mechanism for the susceptibility-associated variant through
interacting at a distance with and modulating expression of the
brain-expressed leucine-rich repeat and immunoglobulin (LIG)
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family protein gene ISLR2. We found no evidence for pathogen
genetics affecting the severity of disease, whereas human genetics
explained 49% ± 9% of this variation. In our Dutch cohort, var-
iation near UBE2U and ROR1 was signiﬁcantly associated with
severity.
The MeninGene cohort also allowed a joint analysis of bacterial
and human sequencing data. The high dimension of interaction
data necessitates more samples than we were able to collect to
ﬁnd interaction effects of modest effect sizes, but through biolo-
gically guided dimension reduction we were able to show possible
evidence for enrichment of certain pathogen genotypes in certain
host genotypes. Owing to the approach of testing only speciﬁc
candidates to reduce multiple testing burden, these results should
be seen as speculative and as possible targets of future validation
attempts.
Systematic surveys of genomic variation affecting infectious
disease susceptibility and progression are a complementary
approach for studying pathogenesis. The complexity and cost of
an appropriate laboratory-based model negates the possibility of
studying the effect of all host and pathogen genes on virulence
using traditional wet-laboratory approaches. By combining large
sequenced cohorts with clinical metadata, we were able to test for
an effect of all observed sequence variants in both the host and
pathogen, in the natural host. While ﬁnding associated human
variants proved relatively challenging, as has been the case with
other infectious diseases, our pGWASs found serotype-
independent genes potentially involved in invasiveness. The
inherent advantages of GWASs make joint analysis of human and
bacterial genetics in other studies of infectious disease a useful
approach, especially if both genomes can be collected
concurrently.
Methods
Ethics statement. For the MeninGene study, written informed consent was
obtained from all patients or their legally authorized representatives. The study was
approved by the Medical Ethics Committee of the Academic Medical Center,
Amsterdam, The Netherlands (approval number: NL43784.018.13). For bacterial
carriage samples from The Netherlands, written informed consent was obtained
from both parents of each child participant and from all adult participants.
Approvals for the 2009 and 2012/2013 studies in children and their parents
(NL24116 and NL40288/NTR3614) and for the study in elderly adults (NTR3386)
were received from a National Ethics Committee in The Netherlands (CCMO and
METC Noord-Holland). For the 2010/2011 study, a National Ethics Committee in
The Netherlands (the STEG-METC, Almere) decided that approval was not
necessary. The studies were conducted in accordance with the European State-
ments for Good Clinical Practice and the Declaration of Helsinki of the World
Medical Association. The Danish Invasive Pneumococcal Disease Cohort was
approved by Danish Data Protection Agency (record no. 2007–41–0229 and 01864
HVH-2012–046). Ethical permission was obtained from The Ethical Committee of
The Capital Region of Denmark (H-B-2007–085 and H-1–2012–063). According to
Danish Legislation, the Research Ethics Committee can grant an exemption from
obtaining informed consent for research projects based on biological material
under certain circumstances, and for this study such an exemption was granted.
Cohorts collected. For MeninGene, we prospectively included patients of ≥16
years with CSF culture-proven bacterial meningitis between March 2006 and July
2015. Patients were identiﬁed from the database of The Netherlands Reference
Laboratory for Bacterial Meningitis (NRLBM), which receives bacterial strains
cultured from CSF and blood of 85% of community-acquired bacterial meningitis
patients in The Netherlands. The NRLBM provided daily updates of hospitals
in which patients with bacterial meningitis had been admitted in the preceding
2–6 days and names of treating physicians. Physicians were contacted by telephone
by the investigators, informed about the study and asked to include the patient
in the study. Physicians could also contact the investigators to include a patient
without a report of the reference laboratory. Patients or their legal representatives
were provided written information on the study and asked for written informed
consent. Baseline, admission, treatment and outcome data was collected by the
treating physician using an online case record form. Outcome was scored using the
Glasgow Outcome Scale score, a ﬁve-point scale ranging from 1 (death) to 5 (mild
or no disability).
Patients with hospital-acquired bacterial meningitis, deﬁned as occurring
during or within 1 week of hospital admission, were excluded as were those with a
neurosurgical intervention or severe neurotrauma within 1 month before
presentation and those with neurosurgical devices. All Dutch neurologists received
information about MeninGene before and during the study.
Patient blood was collected in sodium/EDTA tubes and sent to the Academic
Medical Centre, Amsterdam for DNA extraction. DNA was isolated with the
Gentra Puregene Isolation Kit (Qiagen), and quality control procedures were
performed to determine the yield and purity.
Pathogens were stored at −80 °C in the NRLBM upon receipt. Isolates were
recultured from frozen stock on blood agar plates, from which DNA was extracted
directly. Sequencing was performed using multiplexed libraries on the Illumina
HiSeq platform to produce paired end reads of 100 nucleotides in length (Illumina,
San Diego, CA, USA).
Controls for the Dutch meningitis susceptibility GWAS and heritability analysis
have been composed of the healthy adult controls from the amyotrophic lateral
sclerosis (ALS) and B-Vitamins for the PRevention Of Osteoporotic Fractures (B-
PROOF) cohorts59,60.
For the Danish Childhood Pneumococcal Disease Cohort, cases of IPD in
children aged <5 years were identiﬁed through the National Neisseria and
Streptococcus Reference Laboratory, Statens Serum Institut (SSI), Copenhagen,
Denmark61. DNA was obtained from the Danish Neonatal Screening Biobank
(DNSB), SSI. Cases with a prior hospitalization for any cause were excluded in
order to exclude children with severe comorbidity. Information on hospitalization
was obtained from the Danish National Patient Register. Genomic DNA was
extracted from dried blood spots using the Extract-N-Amp Kit (Sigma-Aldrich)
and the REPLI-g Mini Kit (Qiagen). Cases were genotyped on the Illumina HiScan
platform with the Human Omni1-Quad beadchip. As population-matched controls
for the Danish collection, we used the genotypes of 2805 randomly sampled healthy
Danish young adults from the GOYA study (Genomics of extremely Overweight
Young Adults)62.
For Genetics of Sepsis and Septic Shock in Europe (GenOSept), cases were
deﬁned as patients with conﬁrmed septic shock managed in an intensive care
environment recruited as part of the GenOSept consortium with a diagnosis of
pneumococcal infection conﬁrmed using either blood cultures positive for S.
pneumoniae or positive pneumococcal urinary antigen. Population controls were
derived from the Wellcome Trust Case Control Consortium 2 1958 Birth Cohort
(dbGaP accession phs900028.v1.p1). The GenOSept cases were genotyped on the
Affymetrix 5.0 and the WTCCC2 controls on the Affymetrix 6.0 arrays and were
quality checked in parallel using the following steps. After mapping SNPs to build
37 coordinates samples with call rates either <98% or those with mismatching
reported and genetically deﬁned sex or with relatedness IBD score >0.2 were
removed. SNPs with call rates <98% or Hardy–Weinberg equilibrium (HWE)
p <1 × 10–10 or MAF < 1% were also removed. Finally, multidimensional scaling
(MDS) was used to deﬁne sample ancestries and any outliers based on either MDS
or heterozygosity (>3 standard deviations around the mean) were removed.
Intersecting SNPs between the two arrays were then used as a scaffold for variant
imputation that was performed simultaneously using SHAPEIT and IMPUTE2.2
using the 1000 Genomes phase 1 variant set release. Default settings were used
throughout phasing and imputation steps. Association testing of imputed
probabilities was performed using SNPTEST version 2.4.0 using additive
frequentist methods tests using the ﬁrst 4 MDS components as covariates.
Summary statistics were obtained from this susceptibility GWAS of severe
pneumococcal infection63.
From UK Biobank, we extracted case samples with self-reported meningitis or
sepsis/septicaemia (data-ﬁeld 20002), with a diagnosis of meningitis (data-ﬁeld
41202 having a value of G01, G001, G002, G003, G008, A170, A390 or A321 at
least once) and with a diagnosis of sepsis (A403, A409, A408 or A40 at least once).
We randomly selected 3000 control samples from the remaining samples that had
passed the UK Biobank's genetic quality control step, which allowed for quicker
analysis with little impact on effective sample size.
Summary statistics were obtained from a GWAS of bacterial meningitis
performed by 23andme, with cases deﬁned by those who responded yes to the
question ‘Have you ever had bacterial meningitis?’8.
Carriage of S. pneumoniae in Dutch adults and children was determined by
conventional culture in vaccinated children (11 and 24 months of age) and their
parents/adults in 200964, 2010/201164 and 2012/201365 and in community-
dwelling elderly adults in 2011–201366. All children were vaccinated with PCV-7 or
PHiD-CV10 according to the Dutch national immunization program at 2, 3, 4 and
11 months of age. Nasopharyngeal swabs were collected from all individuals and
oropharyngeal swabs were collected from all adult subjects by trained study
personnel using ﬂexible, sterile swabs according to the standard procedures
described by the World Health Organization67. After sampling, swabs were
immediately placed in liquid Amies transport medium, transported to the
microbiology laboratory at room temperature and cultured within 12 h. From
elderly participants, saliva was also collected using Oracol Saliva Collection System
(Malvern Medical Developments Ltd, Worcester, UK), immediately transferred to
tubes pre-ﬁlled with glycerol and transported to the diagnostic laboratory on dry
ice66. After being cultured for S. pneumoniae, samples from adults were tested for
pneumococci with molecular diagnostic methods66,68. Samples identiﬁed as
positive with molecular methods, yet negative when cultured at primary diagnostic
step were revisited with culture in the second attempt to isolate live pneumococci69.
Pneumococcal isolates were identiﬁed using conventional methods; one
pneumococcal colony per plate was subcultured (more if distinct morphotypes
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were observed) and serotyped by capsular swelling (Quellung). DNA extraction
and sequencing was performed as for the MeninGene study.
In the South African cohort, pneumococcal isolates from disease were identiﬁed
in a national, active, laboratory-based surveillance for IPD—deﬁned as isolation
from a normally sterile site—by the National Institute for Communicable Disease,
Johannesburg between 2005 and 201470. Pneumococcal isolates from
asymptomatic carriage were collected in two cross-sectional colonization surveys in
Agincourt and Soweto between 2009 and 201371. Isolates from these collections
were randomly subsampled for sequencing on Illumina HiSeq (as for the
MeninGene study) within the age groups ≤2 (50%), >2–≤5 (25%) and >5 (25%).
Serotyping was performed using Quellung and DNA was extracted from single
colony subcultures from stocks stored at −80 °C.
Cataloguing bacterial variation. From the whole-genome sequence data of bac-
teria in the cohort, we called SNPs and short INDELs with respect to the ATCC
700669 reference72. We mapped reads with bwa mem73 and marked optical
duplicates with Picard. Using this mapping, we used cn.mops74 to call copy
number variations (CNVs). We used windows of 1 kb and used windows with
support for a CNV in at least two samples. The number of reads mapping to each
ivr allele in each sample was determined by counting correctly oriented mapped
read pairs spanning the repeats in the locus16,75.
SNPs and INDELs were then called with GATK HaplotypeCaller76. For
INDELs, we used the recommended hard ﬁlters. For SNPs, we used the
recommended hard ﬁlters to create an initial call set. We then applied GATK
VariantRecalibrator using the following call sites as true positive priors: the
intersection of SNPs called by both GATK and bcftools (Q10; 90% conﬁdence);
ﬁltered SNPs from a carriage cohort of Karen infants77 (Q5; 68% conﬁdence);
ﬁltered SNPs from a carriage cohort of children in Massachusetts36 (Q5; 68%
conﬁdence). After quality score recalibration, we used 99.9% recall as a cutoff for
SNPs to maximize sensitivity and annotated the predicted effect of all coding
variation using the variant effect predictor78. We deﬁned LoF variants as either
stop gained or frameshift mutations. We used PROVEAN with a score cutoff of <
−2.5 to predict whether non-synonymous SNPs affect protein function79.
We counted variable length k-mers with a minor allele count of at least ten
using fsm-lite18. In the Dutch data, there were 11.7M informative k-mers, with
2.6M unique patterns. While the k-mer approach should directly assay or tag most
variation at the population level, the allelic variation of the pneumococcal antigens
may not be well captured. For example, pspC can be difﬁcult to assemble due to
repeats and CNV80, and k-mers from pspA and zmpA may not map to each allele
speciﬁcally due to orthologous and paralogous genes35,81. We developed a more
accurate way to classify the allele present in each isolate combining assembly and
mapping statistics. For each antigen in each sample, we mapped reads to a
reference panel using srst282 and aligned annotated genes from the assemblies
using blastp. We then built a classiﬁer using the summary statistics reported by
these programs. For pspC, we used an existing classiﬁcation scheme of 11 alleles
from 48 sequences as training data (Supplementary Fig. 16)80. For zmpA and pspA
training data, we built trees from previously characterized alleles27 (Supplementary
Figs. 17 and 18), which allowed us to deﬁne four allele groups for pspA and three
for zmpA. We ensured that the unlabelled training data were separable into these
groups using principal component analysis (PCA; Supplementary Fig. 19). We
tested the performance of four out-of-the-box classiﬁers on 20 pspC alleles spread
across the population that we manually typed from the assemblies (Supplementary
Table 9). Finding that a support vector machine with a linear kernel worked best,
we used this to classify the allele of all antigens in all isolates using the summary
statistics described above (Supplementary Fig. 20).
Using the South African samples, we counted k-mers, SNPs and INDELs and
COGs in the same way and annotated LoF function variants. We found 52,215
SNPs and INDELs, 6.3M informative k-mers, with 1.5M unique patterns.
Association of bacterial variation. Using the SNP and INDEL alignment, we built
a phylogenetic tree from this alignment using fasttree83 and calculated the kinship
(covariance matrix) between each pair of strains as the distance between their
MRCA and the midpoint root84. All heritabilities and variance components were
calculated with the limix package (v2.0.0)85. We calculated the heritability of each
phenotype using this kinship matrix and Bernoulli errors. To estimate the herit-
ability due to serotype alone, we performed the same calculation but with the
kinship matrix calculated from a genotype matrix that treats each possible serotype
as a genetic variant. Owing to the relative sparsity of serotype observations, it was
not possible to do this analysis for individual phenotypes. We repeated both of
these analyses while using the top ten principal components of a PCA of the
genotype matrix (67% variance explained) as covariates. Finally, we performed
variance decomposition using these two kinship matrices to split the detected
heritability into components due to serotype, other genetics and residuals86. This
required treating invasiveness as a continuous phenotype. We also tested whether
the effect of serotype on invasiveness could be explained by capsule charge on
phenotype, by using previously measured zeta potentials in place of serotype87,
using the serogroup average when a serotype-speciﬁc charge was not known.
Invasiveness was not well predicted from capsule charge alone (R2= 0.08)88, partly
because of the unknown capsule charge for many of the serotypes observed.
For association of common variation (MAF > 1%), we compared SEER18, using
the ﬁrst ten MDS components as ﬁxed effects to control for population structure,
with FaST-LMM85, which uses eigenvectors from the kinship matrix calculated
from the SNP and INDEL alignment as random effects to control for population
structure. The Q-Q plots using ﬁxed effects were highly inﬂated (Supplementary
Fig. 21), so we used the linear mixed model throughout. To correct for multiple
testing, we used the number of unique patterns as the number of tests in a
Bonferroni correction, giving p < 8.2 × 10–7 for SNPs and p < 1.9 × 10–8 for k-mers.
Inspection of the Q-Q plots showed inﬂation of the test statistic for k-mers, so we
used a higher threshold of p < 10–16 instead. The same association methods was
used with the antigen alleles and CNVs.
We considered whether the ivr locus, a phase variable inverting type I R-M
system with six possible alleles75, is associated with meningitis, as has been
previously shown using mouse models of disease29,88. The rapid variation of this
locus allows simple associations independent of genetic background. To test for
association of the ivr locus alleles with susceptibility and severity, we used a
Bayesian hierarchical model to ﬁnd differences in the proportion of alleles present
in tissue types while accounting for heterogeneity within single colony picks16. We
found no evidence that either allele frequencies or overall diversity had any
association with invasive disease or carriage in clinical cases of meningitis
(Supplementary Figs. 22 and 23).
We calculated Tajima’s D for all coding sequences annotated in the ATCC
700669 reference, ignoring gaps or unknown sites and calculated p values for
difference between niche using null permutations of phenotype labels89. We
applied a Bonferroni correction using the number of coding sequences tested
multiplied by the number of association techniques (three), with the number of
null permutations (44,000) chosen allowing for detection of signiﬁcance at this
adjusted threshold.
Rare variants (MAF < 1%) were associated by grouping variants by coding
sequence in a burden test, in which we treated samples with a mutation anywhere
in the gene as the alternate allele and unmutated genes as the reference allele90. As
these burden tests lose power when variants have different directions of effect on
the phenotype, we used only those variants predicted to cause a LoF in one test,
and those causing either LoF (6825 variants) or predicted change in protein
function in another (additional 26,206 variants). We used plink/seq to perform this
association for each phenotype, applying a Bonferroni correction using the number
of genes as the number of multiple tests (‘burden of rare LoF/missense’ in Table 1).
We then repeated this using the LMM burden testing mode of pyseer91, which
allowed us to correct for population structure with the same model as above.
Reasoning that power to detect individual variants may also be hampered by
population structure as well as allele frequency, we also searched for a burden of
missense variants of any frequency by gene (‘missense burden’ in Table 1), though
this test would be insensitive to genes where missense variants have different
directions of effect. For this test, we classiﬁed samples containing a missense
variant anywhere in the gene as the alternative allele. We excluded sequences which
appeared to be pseudogenes in the population, as the variant annotation is no
longer likely to be meaningful. To attempt to calculate heritability due to rare
variation, we used these deﬁnitions of burden to form a genotype matrix. We were
unable to ﬁnd signiﬁcant evidence for h2burden > 0 for any individual gene or over
all genes. We were also unable to separate out this variance component from the
overall estimated heritability from core SNPs h2SNP. Rather than ruling out a role
for rare variation in pathogenesis, this is instead likely due to a combination of
methodological factors: a small genotype matrix limited by the number of genes,
rarity of mutations even when aggregated, and potentially grouping variants with
different directions of effect on invasiveness.
When performing meta-analysis with both the Dutch and South African
samples, we pooled the genetic data and performed the same association analysis as
for the Dutch data alone. Where possible, we included country as a covariate. The
South African cohort also included host gender, age, collection year and HIV status
and PCV use at the time of sampling. We included these as additional covariates
for these samples. We performed a burden test using only damaging LoF variants.
We used a signiﬁcance threshold of p < 0.05 in the pooled analysis, after applying a
Bonferroni correction for multiple testing based on the number of unique patterns
as above. For all tests, we ensured that the Q-Q plots of the resulting p values were
not inﬂated (Supplementary Fig. 24).
Human genotyping and quality control. We performed genotyping using the
Illumina Omni array and called genotypes from normalized intensity data using
optiCall92. For data taken from other platforms, we merged cases and controls only
at sites in the intersection of the genotyping arrays used. We then performed basic
quality control steps to ﬁrst remove low quality samples, then low quality mar-
kers93. Samples with a heterozygosity rate three standard deviations away from the
mean or >3% missing genotypes were removed. Markers with >5% missing gen-
otypes, signiﬁcantly different (p < 10–5) call rate between cases and controls, MAF
< 1% or out of HWE (p < 10–5) were removed. Using an LD-pruned set of markers,
we estimated sample relatedness with KING94 and removed any duplicate samples.
Using the same set of markers, we used eigenstrat to perform a PCA to check
sample ancestry (Supplementary Fig. 25)95. Samples closer than third-degree
relation and samples of non-European ancestry (which we deﬁned as PC1 < 0.07)
were removed for heritability analysis. We manually inspected intensity plots for
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any associated markers using Evoker96 and removed any miscalled sites. Finally, we
removed markers signiﬁcantly associated with control batch (p < 5 × 10–8).
All markers were reported with respect to the reference allele and coordinates of
GRCh37. We imputed markers using the HRC as a reference panel with the Sanger
Imputation Server97–99. For the Danish samples, we instead used the Michigan
imputation server due to the decreased number of markers available from merging
two different genotyping arrays100. For greater accuracy, the CFH region was
imputed using impute2 with 1000 Genomes and GoNL as reference panels101–103.
We removed resulting markers with MAF < 1%, HWE p < 10–5 or INFO scores
<0.7 leaving 6.8M markers for association testing and heritability estimation.
Association of human variation. Throughout we used a Glasgow Outcome Scale
score104 of <5 to deﬁne unfavourable outcome, as described previously4. We
performed the association study using bolt-lmm44,105, using the LD-pruned set of
genotyped markers to estimate the kinship matrix, and then calculating association
statistics for all genotyped and imputed sites passing the above quality control
thresholds. For the Dutch samples, we included whether the patient was immu-
nocompromised as a ﬁxed effect (10% of cases), assuming that no control samples
were immunocompromised (1% population prevalence106,107). To estimate herit-
ability, we used two methods: GCTA-GREML108 (as implemented in bolt-lmm)
and LDAK v5109. For both, we only used samples passing the stricter thresholds for
ancestry and relatedness. Estimates of heritability were transformed from the
observed scale to the liability scale using a population prevalence of meningitis of
1 × 10–3.
To perform associations using the UK Biobank, we used bolt-lmm, following
the recommended protocol for analysing the available genetic data110. Using the
sample described above, we removed genotyped markers with MAF < 0.001 or a
missing rate >0.1 and used this to estimate kinships in bolt-lmm. We used bolt-
lmm to perform association analysis of every imputed SNP site, including
participant age as a ﬁxed effect.
We used METAL to perform meta-analysis between different sets of studies111.
We used the effective sample size to weight the beta and SE from each set of summary
statistics, also adjusting the beta values and standard errors produced by bolt-lmm
(Supplementary Table 10). We only retained markers that had been successfully
imputed in all studies, to avoid effects of varying sample size at each locus.
Chromatin conformation capture data were tested and presented using the
Capture HiC Plotter112 and eQTL data from the GTEx Consortium47.
Interaction effects. We took 460 pneumococcal meningitis samples with matched
pathogen and human sequence data that passed quality control thresholds for both
data types. To test all variants in a pairwise manner, we treated human genotypes as
additive and stored site and sample data separately for more efﬁcient access by
chunk113. The number of pairwise tests between all common variants was prohi-
bitively large (1012), so we only tested genotyped markers: 1.8 × 1010 pairs of variants
passed ﬁlters of MAF > 5% and missing rate <5% in both the human and pathogen
data. We modiﬁed the association code of SEER18 to extend the χ2 test to a 3 × 2
table and to perform a 3 × 2 Fisher’s exact test when assumptions of the χ2 test were
violated. Those sites with p < 5 × 10–11 (a Bonferroni correction with α = 1, as an
initial ﬁlter) were then tested using a logistic regression of the human SNP against
the pathogen variant, with the ﬁrst three components from MDS of the pathogen
kinship matrix included as covariates to adjust for pathogen population structure.
To test for an association between invading lineage and human genotype, we
ran hierBAPS on these 460 samples114, which generated ten top-level clusters,
seven of which were large enough to test (Supplementary Table 8). To perform the
association, we used bolt-lmm, as above. We tested association of antigen alleles
with frequencies >10% in the sampled population in the same way (Supplementary
Table 7).
Data availability
Bacterial metadata, including ENA accession numbers for sequencing data, can be
accessed on ﬁgshare 5915314 [https://doi.org/10.6084/m9.ﬁgshare.5915314]. Summary
statistics from the pGWAS can be found on ﬁgshare 7728620 [https://doi.org/10.6084/
m9.ﬁgshare.7728620]. Summary statistics from the hGWAS can be found on Zenodo
2572916 [https://doi.org/10.5281/zenodo.2572916].
Code availability
The code used for the analysis, along with phylogenies and predicted antigen alleles, can
be found at https://github.com/johnlees/meningene (BSD-3 License). In addition, the
following software packages were used: bwa mem (v0.7.10); Picard (v1.124); cn.mops
(v1.28.0); GATK (v3.5.0); Provean (v1.1.5); srst2 (v0.2.0); fasttree (v2.1.8); limix (v2.0.0);
SEER (v1.4.0); FaST-LMM (python) (v0.2.32); plink/seq (v0.09); pyseer (v1.0.2); opticall
(v0.7.0); KING (v1.4); eigenstrat (v10210); Evoker (v2.2); bolt-lmm (v2.3); LDAK (v5.0);
METAL (v2011–03–25); hierBAPS (v6.0).
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